Authors' reply to "Reconsidering prostate cancer screening: limitations of net survival and the primacy of overall survival as an endpoint".

IF 2.5 4区医学 Q3 ONCOLOGY

Japanese journal of clinical oncology Pub Date : 2026-09-09 DOI:10.1093/jjco/hyag076

Rina Tanaka, Michel P Coleman, Masashi Matsuzaka, Hiromi Sugiyama, Veronica Di Carlo, Tomohiro Matsuda, Claudia Allemani

引用次数: 0

查看原文本刊更多论文

作者对“重新考虑前列腺癌筛查：净生存期的局限性和总生存期作为终点的首要地位”的回复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese journal of clinical oncology 医学-肿瘤学

CiteScore

3.70

自引率

8.30%

发文量

177

审稿时长

3-8 weeks

期刊介绍： Japanese Journal of Clinical Oncology is a multidisciplinary journal for clinical oncologists which strives to publish high quality manuscripts addressing medical oncology, clinical trials, radiology, surgery, basic research, and palliative care. The journal aims to contribute to the world"s scientific community with special attention to the area of clinical oncology and the Asian region. JJCO publishes various articles types including: ・Original Articles ・Case Reports ・Clinical Trial Notes ・Cancer Genetics Reports ・Epidemiology Notes ・Technical Notes ・Short Communications ・Letters to the Editors ・Solicited Reviews